熱門資訊> 正文
Veeva与安进合作加快临床试验
2025-08-28 21:30
- Veeva Systems (NYSE:VEEV) said on Thursday it is partnering with Amgen to enhance end-to-end clinical trial operations using the Veeva Clinical Platform, aiming to speed up drug development.
- "In collaboration with Veeva, we're leveraging advanced technology to unlock new capabilities for our end-to-end trial operations which are expected to further strengthen our ability to bring innovative treatments to patients with speed and scale" Amgen CEO, Skellenger said in a statement.
- VEEV -4.63% premarket to $280.0
- Source: Press Release
More on Veeva Systems
- Veeva Systems Inc. (VEEV) Q2 2026 Earnings Call Transcript
- Veeva Systems Inc. 2026 Q2 - Results - Earnings Call Presentation
- Veeva Systems: Growth Momentum Remains Strong
- Veeva signals expanded opportunity in commercial cloud and AI following IQVIA resolution
- Veeva Systems Non-GAAP EPS of $1.99 beats by $0.09, revenue of $789.1M beats by $20.37M
推薦文章
華盛早報 | 突發！納斯達克修改針對中國公司的上市規則；谷歌大漲超9%創新高
美股收盤：標普500指數漲0.51%，納指漲超1%；谷歌漲超9%創歷史新高
外盤頭條：聯儲褐皮書顯示美國經濟陷入停滯 谷歌市值增加2300億美元 沃勒稱美聯儲應本月啟動降息
蘋果暫未受特朗普關税衝擊，但仍有可能提高iPhone售價
美股機會日報 | 壟斷案獲重大勝利，谷歌盤前漲超5%；金價站上3600美元續創歷史新高
中概股Q2業績大比拼：外賣大戰誰贏了？阿里績后單日升逾18%，美團淨利暴跌89%股價重挫12%
卡夫亨氏拆分計劃惹怒巴菲特 穆迪警告或下調其投資級評級
谷歌贏得重大勝利，美法官裁決其無需剝離Chrome瀏覽器和安卓系統
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
